Concept Architecture
Concept
Symptom-Free Survival (SFS) is the length of time from a defined starting point, such as treatment initiation or randomisation, until the onset or recurrence of disease-related symptoms or death, whichever occurs first. It is a time-to-event endpoint that evaluates the duration for which patients remain alive without clinically significant symptoms attributable to the disease. In health economics, symptom-free survival is used to quantify treatment benefit, estimate health state occupancy and inform cost-effectiveness analyses where symptom control is a clinically meaningful outcome.
Mathematically, Symptom-Free Survival is represented by the survival function, which estimates the probability that a patient remains alive without symptoms beyond a specified time. The survival function is commonly estimated using the Kaplan?Meier estimator and may subsequently be modelled using parametric or semi-parametric survival models. Comparative analyses frequently use hazard ratios to quantify differences in symptom-free survival between treatment groups.
In practice, symptom-free survival is measured through prospective patient follow-up using predefined clinical criteria for symptom onset together with survival status. Patients who have not experienced symptoms or death by the end of follow-up are censored. Symptom-free survival estimates are incorporated into health technology assessments and economic models to estimate quality-adjusted survival, resource utilisation and long-term treatment value.
Purpose
Used to quantify the duration of survival without clinically significant symptoms, evaluate treatment effectiveness, compare interventions and provide survival inputs for health economic evaluation.
Mathematical Formulae
Primary Formula
S(t) = P(T > t)
Supporting Formulae
Kaplan?Meier estimator:
?(t) = ?(1 ? d? / n?)
Hazard Ratio:
HR = h?(t) / h?(t)
Related Mathematical Methods
- Kaplan?Meier estimation
- Cox proportional hazards model
- Log-rank test
- Parametric survival modelling
- Restricted Mean Survival Time
- Partitioned survival modelling
Example
A randomised trial follows 420 patients with advanced heart failure after treatment initiation. At 24 months, the Kaplan?Meier estimate of symptom-free survival is 0.64, indicating that 64% of patients remain alive without clinically significant symptoms. These estimates are subsequently used within a partitioned survival model to estimate quality-adjusted life-years and incremental cost-effectiveness.
Excel Implementation
| Function | Example Formula | Health Economics Application |
|---|---|---|
| IF | =IF(OR(C2="Symptoms",C2="Death"),1,0) | Creates the event indicator for symptom-free survival analysis. |
| MIN | =MIN(SymptomDate,DeathDate,CensorDate)-StartDate | Calculates observed symptom-free survival time. |
| MEDIAN | =MEDIAN(B2:B421) | Summarises observed symptom-free survival times. |
| COUNTIFS | =COUNTIFS(C:C,"Censored") | Counts censored observations for survival reporting. |
VBA (Optional)
Automate preparation of symptom-free survival datasets and generation of survival summaries for health economic modelling.
Sources
- Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. Journal of the American Statistical Association. 1958.
- Cox DR. Regression Models and Life-Tables. Journal of the Royal Statistical Society Series B. 1972.
- Drummond MF, et al. Methods for the Economic Evaluation of Health Care Programmes.
- Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation.
- NICE. Health Technology Evaluation Manual.
Related Concepts (2)
Library
Publications
1
Economic Evaluation in Clinical Trials — Glick, Doshi, Sonnad & Polsky, 2nd Edition ed., 2015 (Oxford University Press)
Practical guidance on conducting cost-effectiveness analyses alongside controlled trials, covering trial design, measurement of costs and quality-adjusted life years, handling censored and missing data, and reporting stochastic uncertainty. Volume 4 in the Handbooks in Health Economic Evaluation series.
BookView source →
Frequently Asked Questions (6)
What is symptom-free survival?
A time-to-event measure defined as the time from treatment start until the onset or return of clinically significant symptoms.
Source: Latimer 2013
Why does symptom-free survival focus on time without symptoms?
Symptom-free survival measures the time from the start of treatment until clinically significant symptoms appear or return, focusing on how long a patient stays well rather than merely alive. It reflects that patients value time free of the burdens of their disease, and not merely the length of life, so a treatment that lengthens the symptom-free period offers a benefit that overall survival alone would not capture. It is a step toward measuring quality of survival, not just its duration. Time lived well is its focus. Fleming and DeMets (1996) discuss such endpoints.
Source: Fleming & DeMets 1996
How is symptom-free survival measured?
Symptom-free survival is measured from a defined starting point, such as the start of treatment, until the onset or return of clinically significant symptoms, with patients who remain symptom-free at the end of follow-up censored at their last assessment. Survival analysis methods, such as the Kaplan-Meier estimator, are used, handling censoring appropriately. Defining what counts as clinically significant symptoms and assessing them consistently is needed. Because it depends on detecting symptom onset, symptom-free survival requires regular, consistent symptom assessment to determine when the symptom-free period ends.
Source: Latimer 2013
Why is symptom-free survival used?
Symptom-free survival is used because how long a patient remains free of meaningful symptoms is important to their quality of life, and this measure captures that directly, conveying the duration of symptomatic benefit from treatment. It focuses on the patient's experience of being free from symptoms over time, which matters alongside survival and disease control. Symptom-free survival is relevant where relieving and delaying symptoms is a goal of treatment, providing a time-to-event measure of symptomatic benefit that complements measures of survival and disease markers.
Source: Gelber et al. 1989
What are the limitations of symptom-free survival?
The limitations of symptom-free survival arise because defining clinically significant symptoms and detecting their onset depend on consistent, sensitive assessment, which can vary, affecting the measure, and because symptoms are subjective, their timing may be imprecise. The definition of the qualifying symptoms influences the endpoint, and inconsistent definitions hinder comparison. Its relationship to other outcomes must be considered. These limitations mean symptom-free survival is defined clearly with consistent symptom assessment and interpreted alongside other measures, recognising the subjectivity and definitional choices involved in determining the symptom-free period.
Source: Latimer 2013
How does symptom-free survival relate to quality-adjusted survival measures?
Symptom-free survival relates to quality-adjusted survival measures in that both value time spent in better health states, but symptom-free survival specifically measures time free of significant symptoms, while quality-adjusted measures, such as those in the Q-TWiST framework, weight different periods, including time with symptoms or toxicity, by their quality. So symptom-free survival can contribute to quality-adjusted measures as the period of good-quality, symptom-free time. Both reflect that the quality of survival, not just its length, matters, with symptom-free survival focusing on the duration free of symptoms.
Source: Gelber et al. 1989
Trust Record
Verified by Dr Darrin Baines
British health economist
Professional identity: darrinbaines.org
Verification date: 11 Nov 2025
Content version: 1.0.0
Canonical Identity
- Term code
- HE-ES-CO-087
Stable URI · Machine-readable · Resolvable · CC BY 4.0